Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|April 2, 2004
- Pharmaceutical Technology-04-02-2004
- Volume 28
- Issue 4
Controlled-Release Dosage Forms for Diltiazem Hydrochloride
Author(s)Ramesh Panchagnula, PhD
The authors investigate whether an extrusion-spheronization proces can be used to develop a matrix-based, controlled-release formulation for a highly water-soluble drug.
Advertisement
Articles in this issue
over 22 years ago
Spotlight on Business Riskover 22 years ago
Vibration Technology for Active Dry-Powder Inhalersover 22 years ago
In the Spotlight April 2004over 22 years ago
FDA Attacks Counterfeitsover 22 years ago
Synthetic Excipients Challenge All-Natural Organicsover 22 years ago
April 2004Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement